Frontlight ResearchEarly access
Taking people in SwedenPhase 1
Brain imaging of alpha-7 nicotinic receptors in Alzheimer's disease and mild cognitive impairment
Uses brain scans to study nerve cell proteins in Alzheimer's disease and healthy volunteers.
Key facts
- Who runs it
- Karolinska Institutet
- Where
- Huddinge and Solna, SwedenSee the 3 sites
- Trial code
- Registry title
- A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and Alzheimer´s disease.
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 45 people, planned
- Started
- 16 Feb 2026
- Planned end
- 31 Mar 2026
- Type of study
- Interventional
- Record updated
- 18 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers and for people with mild cognitive impairment or Alzheimer's disease, for a brain scan study.
- Age
- 18 years or older
- Sex
- Women and men can join
- Disease stage
- Healthy volunteers, or people with mild cognitive impairment or Alzheimer's disease
Where in Sweden
- Karolinska InstitutetHuddinge, SwedenTaking people
- CTC Clinical Trial Consultants ABSolna, SwedenTaking people
- Karolinska InstitutetSolna, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Brain imaging of alpha-7 nicotinic receptors in Alzheimer's disease and mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 March 2026